Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11
|
作者：
Liu, Ning [1 ]
Yan, Limei [1 ]
Shan, Fengping [2 ]
Wang, Xiaonai [2 ]
Qu, Na [3 ]
Handley, Mike K. [4 ]
Ma, Mingxing [5 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China
[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China
[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA
[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
来源：
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期
关键词：
Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;
D O I：
10.1016/j.tranon.2021.101028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [42] CD38 is involved in cell energy metabolism via activating the PI3K/AKT/mTOR signaling pathway in cervical cancer cells
    Liao, Shan
    Liang, Lin
    Yue, Chunxue
    He, Junyu
    He, Zhengxi
    Jin, Xi
    Luo, Gengqiu
    Zhou, Yanhong
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 57 (01) : 338 - 354
  • [43] To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway
    Zhong, Jiateng
    Ding, Shuang
    Zhang, Xinyu
    Di, Wenyu
    Wang, Xiaohui
    Zhang, Hui
    Chen, Yiyang
    Zhang, Yongxi
    Hu, Yuhan
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (02): : 37
  • [44] Ilicicolin C suppresses the progression of prostate cancer by inhibiting PI3K/AKT/mTOR pathway
    Gan, Xia
    Luo, Xiaowei
    Chen, Jingqin
    Fang, Wenxuan
    Nie, Mingyi
    Lu, Humu
    Liu, Yonghong
    Wang, Xueni
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2025, 480 (02) : 1089 - 1104
  • [45] The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy
    Bahrami, Afsane
    Hasanzadeh, Malihe
    Hassanian, Seyed Mahdi
    ShahidSales, Soodabeh
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (12) : 4163 - 4169
  • [46] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [47] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : 335 - 342
  • [48] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
  • [49] The Role of the PI3K/AKT/mTOR Signalling Pathway in Male Reproduction
    Deng, Chun-Yan
    Lv, Mei
    Luo, Bin-Han
    Zhao, Si-Ze
    Mo, Zhong-Cheng
    Xie, Yuan-Jie
    CURRENT MOLECULAR MEDICINE, 2021, 21 (07) : 539 - 548
  • [50] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543
12345